Join us for the 2025 Advancing Generic Drug Development Workshop! FDA experts will demonstrate the FDA’s Generic Drug User Fee Amendments (GDUFA) Science and Research Program’s transformative impact on generic drug development, regulation, and approval.
Similar Posts
Citalopram (marketed as Celexa) Information
Citalopram (marketed as Celexa) InformationGuangxi Yulin Pharmaceutical Group Co. Ltd. – 710422 – 09/30/2025
CGMP/Finished Pharmaceuticals/AdulteratedPurity Products Announces Recall on the Dietary Supplement, My Bladder Because of Possible Health Risk
Plainview, NY. October 27, 2025— Purity Products is announcing a recall of one lot of of its dietary supplement MyBladder because it has the potential to be contaminated with Escherichia coli O7:K1 and 1303. The presence of these E. coli strains may pose a risk for gastrointestinal or other infectioAquastar (USA) Corp Recalls Shrimp Because of Possible Health Risk
October 17, 2025, AquaStar (USA) Corp of Seattle, WA is voluntarily recalling a limited quantity of frozen shrimp imported from Indonesia because they may have been prepared, packed, or held under conditions whereby they may have become exposed to very low levels of cesium-137 (Cs-137).Made Fresh Salads, Inc. Recalls Assorted Flavors of Cream Cheese Because of Possible Health Risk
Made Fresh Salads, Inc. of Bay Shore, NY is recalling assorted flavors of cream cheese because they have the potential to be contaminated with Listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakenBiosimilars Research: Awards
Biosimilars Research: Awards